Share:
What Happened: Medical technology company
Senseonics Holdings (NYSE: SENS) reported results from a PROMISE study evaluating its Eversense CGM System for up to 180 days. The Eversense CGM is a continuous glucose monitoring device.
The overall mean absolute relative difference was 9.1% for the primary sensor and 8.5% for the SBA sensor. The study included over 49,000 paired points for the primary sensor and over 12,000 paired points for the SBA sensor.
The confirmed hypoglycemic alert detection rate was 93% for the primary sensor and 94% for the SBA sensor.
No serious negative events were reported from 181 study participants. A reported 1.1%% of patients had a mild infection at the procedure site.
Market Recap With Jim Cramer: Buy Tesla, Gap, Nvidia, Roblox and Wynn
TheStreet recaps the 10 best stories with Jim Cramer from the past week including Cramer s approach to cryptocurrency, updates on meme stocks, his view of Virgin Galactic and more.
Author:
May 31, 2021 8:00 AM EDT
In the most recent Mad Money program, TheStreet s Jim Cramer said Wall Street s first reactions are almost always wrong. Investors who rush to judgment lose out.
Over on Real Money, Cramer took a closer look at the real numbers behind those at first-blush impressions, and talked with the top executives at Salesforce.com (
Snowflake (
SNOW) - Get Report in its latest quarter again posted a doubling of revenue, but losses also widened faster than expected. Cramer tweeted Wednesday that, SNOW is growing faster, not slower, and is growing like mad in Asia and Europe.
/PRNewswire/ Patient Discovery Solutions, a leader in patient-provider engagement technologies which harness the power of real-world data to achieve better.
The list is a little heavy on the tech side. That’s only natural, because the technology sector has spawned so many high growth stocks. However, there’s a little something here for everyone.
Growth Stocks: Abbot Laboratories (ABT)
Source: Sundry Photography/Shutterstock.com
Abbot Laboratories produces a wide range of high-tech medical devices. Products like diagnostic equipment, remote heart monitors, chronic pain treatment and diabetes management systems including a glucose monitoring technology that eliminates the need for pinpricks. The company also produces a range of popular health nutrition products including Pedialyte, Similac and Ensure.
Over the past five years, ABT stock has delivered a return of 216%. That’s nothing to sneeze at. That’s especially true given our aging population, rising diabetes and heart disease rates. As well as the recent push to cut down on subscribing opioids for chronic pain management. All of these factors will add to ongoing growth
Fundamental Context
The CFRA Focus ETF for May is Health Care Select Sector SPDR (XLV). In rating equity ETFs, CFRA combines fund-level attributes, including performance and costs, with holdings-level risk and reward analysis to provide a second opinion on what is inside the fund. XLV is appealing to CFRA as we look forward. Sam Stovall, CFRA’s Chief Investment Strategist, noted that the S&P 500 Index has typically struggled during the seasonally weak May-October period of the year, rising only 2.2% on average since 1990. However, the S&P 500 Health Care sector was the best performing sector gaining 4.8%.
The S&P 500 Health Care sector, which XLV seeks to replicate is diversified across key health care industries. Health Care Equipment & Supplies (29% of assets), Pharmaceuticals (27%), Health Care Providers & Services (20%) are the largest, but the ETF has meaningful exposure to Biotechnology (14%) and Life Sciences Tools & Services (9%) as well. The ETF is market-cap weighted wi